25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
Intralesional methotrexate effectively treats alopecia areata by reducing TNF-α levels, leading to hair regrowth.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
5 citations
,
January 2021 in “Daru” A woman had severe reactions to methotrexate, including skin issues and organ problems, but improved after 38 days in the hospital.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
January 2013 in “Biology of blood and marrow transplantation” Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
June 2026 in “Indian Journal of Postgraduate Dermatology” A 50-year-old man undergoing treatment with the epidermal growth factor receptor inhibitor (EGFRI) lapatinib for stage 2 breast carcinoma developed a papulopustular rash, a common side effect of EGFRIs, affecting 50-100% of patients. This rash, part of the 'PRIDE' complex, includes various cutaneous adverse effects such as xerosis and eczema. The patient was treated with doxycycline and hydrocortisone cream, showing significant improvement within a week. Acneiform eruptions, which lack comedones, may serve as a potential marker for therapeutic response to EGFRI drugs, although evidence is inconsistent. The rash typically appears within 1-2 weeks of therapy, peaks at 3-4 weeks, and subsides gradually. Patients are advised on sun protection and gentle skincare to manage symptoms.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
6 citations
,
June 1986 in “The Journal of Dermatology” Reticular erythematous mucinosis syndrome can occur with minimal mucin deposition.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
10 citations
,
August 2022 in “JAAD Case Reports” Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.
18 citations
,
March 1990 in “Archives of Dermatology” Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.
February 2026 in “ACS Omega” The hydrogel effectively treats oral mucositis by reducing oxidative damage and bacterial infection.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
January 2024 in “Journal der Deutschen Dermatologischen Gesellschaft” Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.
February 1961 in “The Lancet” Some new drugs show potential for treating blood cancers but have serious side effects and need more research.
September 2018 in “PubMed” New strategies like vitamin A and dextromethorphan can help reduce methotrexate side effects and improve patient adherence.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
October 2023 in “Indian Journal of Skin Allergy” Nab-paclitaxel chemotherapy can rarely cause lupus-like skin issues.
21 citations
,
July 2011 in “Journal of the American Academy of Dermatology” A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.